{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:35:17Z","timestamp":1762608917686},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1245\/s10434-022-12468-2","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T15:02:50Z","timestamp":1662994970000},"page":"1663-1668","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing"],"prefix":"10.1245","volume":"30","author":[{"given":"Brittany L.","family":"Murphy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica M.","family":"Gutierrez Barrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debu","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly K.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banu K.","family":"Arun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"12468_CR1","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1245\/s10434-012-2774-8","volume":"20","author":"M Yi","year":"2013","unstructured":"Yi M, Cormier JN, Xing Y, et al. Other primary malignancies in breast cancer patients treated with breast-conserving surgery and radiation therapy. Ann Surg Oncol. 2013;20:1514\u201321.","journal-title":"Ann Surg Oncol."},{"key":"12468_CR2","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2022. Retrieved 22 September 2021 at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf."},{"key":"12468_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.canrad.2016.07.101","volume":"21","author":"L Bazire","year":"2017","unstructured":"Bazire L, De Rycke Y, Asselain B, et al. Risks of second malignancies after breast cancer treatment: long-term results. Cancer Radiother. 2017;21:10\u20135.","journal-title":"Cancer Radiother"},{"key":"12468_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10549-007-9509-8","volume":"106","author":"LM Brown","year":"2007","unstructured":"Brown LM, Chen BE, Pfeiffer RM, et al. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat. 2007;106:439\u201351.","journal-title":"Breast Cancer Res Treat"},{"key":"12468_CR5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0360-3016(01)01665-0","volume":"51","author":"B Fowble","year":"2001","unstructured":"Fowble B, Hanlon A, Freedman G, et al. Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys. 2001;51:679\u201390.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"12468_CR6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S0360-3016(01)02661-X","volume":"52","author":"S Galper","year":"2002","unstructured":"Galper S, Gelman R, Recht A, et al. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:406\u201314.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"12468_CR7","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/sj.bjc.6604241","volume":"98","author":"YM Kirova","year":"2008","unstructured":"Kirova YM, De Rycke Y, Gambotti L, et al. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer. 2008;98:870\u20134.","journal-title":"Br J Cancer."},{"key":"12468_CR8","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1002\/ijc.21651","volume":"118","author":"L Mellemkjaer","year":"2006","unstructured":"Mellemkjaer L, Friis S, Olsen JH, et al. Risk of second cancer among women with breast cancer. Int J Cancer. 2006;118:2285\u201392.","journal-title":"Int J Cancer."},{"key":"12468_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1748-717X-5-104","volume":"5","author":"S Heymann","year":"2010","unstructured":"Heymann S, Delaloge S, Rahal A, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol. 2010;5:104.","journal-title":"Radiat Oncol."},{"key":"12468_CR10","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1002\/cncr.30248","volume":"122","author":"PL Mai","year":"2016","unstructured":"Mai PL, Best AF, Peters JA, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016;122:3673\u201381.","journal-title":"Cancer"},{"issue":"1","key":"12468_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10689-019-00153-5","volume":"19","author":"V Petry","year":"2020","unstructured":"Petry V, Bonadio RC, Cagnacci AQC, et al. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome). Fam Cancer. 2020;19(1):47\u201353.","journal-title":"Fam Cancer"},{"key":"12468_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10549-004-2472-8","volume":"89","author":"C Rubino","year":"2005","unstructured":"Rubino C, Shamsaldin A, Le MG, et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat. 2005;89:277\u201388.","journal-title":"Breast Cancer Res Treat"},{"key":"12468_CR13","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1002\/cam4.1698","volume":"7","author":"SH Salminen","year":"2018","unstructured":"Salminen SH, Sampo MM, Bohling TO, et al. Radiation-associated sarcoma after breast cancer in a nationwide population: increasing risk of angiosarcoma. Cancer Med. 2018;7:4825\u201335.","journal-title":"Cancer Med"},{"key":"12468_CR14","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0360-3016(01)02799-7","volume":"52","author":"J Yap","year":"2002","unstructured":"Yap J, Chuba PJ, Thomas R, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:1231\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"12468_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ijrobp.2020.02.020","volume":"107","author":"S Schlosser","year":"2020","unstructured":"Schlosser S, Rabinovitch R, Shatz Z, et al. Radiation-associated secondary malignancies in BRCA mutation carriers treated for breast cancer. Int J Radiat Oncol Biol Phys. 2020;107:353\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"12468_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/CEJ.0b013e3282f75ee5","volume":"17","author":"L Sanchez","year":"2008","unstructured":"Sanchez L, Lana A, Hidalgo A, et al. Risk factors for second primary tumours in breast cancer survivors. Eur J Cancer Prev. 2008;17:406\u201313.","journal-title":"Eur J Cancer Prev"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12468-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12468-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12468-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T21:30:39Z","timestamp":1675891839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12468-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["12468"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12468-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"16 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Kelly Hunt is on the Medical Advisory Board of Armanda Health and AstraZeneca and receives research funding to the University of Texas MD Anderson Cancer Center from Cairn Surgical, Eli Lilly and Co, and Lumicell. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}